Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer's Disease (CTAD) Asia and Alzheimer's Association International Conference (AAIC)
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer's Disease (CTAD) Asia conference in Shanghai, China. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center at Las Vegas, will present an oral communication titled, "Cognitive Evaluation of Treatment Effects of the Bromodomain and Extra-terminal Inhibitor Apabetalone; Design and Baseline Data of the Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial" which will highlight the design and baseline characteristics of a prespecified substudy of cognition in elderly patients in the Company's ongoing phase 3 BETonMACE clinical trial. Cognition is being assessed using the Montreal Cognition Assessment (MoCA) in patients 70 years and older at baseline, one-year, two-year and at end of study. In addition, Dr. Cummings will present a poster titled, "Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients," illustrating new data from the proteomic analysis from the Company's phase 2 ASSURE clinical trial. The poster will highlight data on proteins that are linked to cognitive decline and neurodegenerative disease and may contribute to neuroplasticity, blood-brain barrier integrity and mitochondrial function. The Company will also highlight the design of the cognition substudy in BETonMACE at a poster presentation at the Alzheimer's Association International Conference (AAIC) in Chicago, USA.
Hemostemix Formalizes World-Class Scientific Advisory Board
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board ("SAB"). Members of the SAB are all leaders in their fields of expertise, which span biochemistry, molecular biology, genomics and medicine. The mandate of the Scientific Advisory Board will be to serve as a strategic resource for Hemostemix to advise on research and development initiatives surrounding its stem cell technology product pipeline and the furtherance of Hemostemix's clinical pipeline and support the Company's overall mission. Members of the SAB are:
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that BETonMACE, Resverlogix's on-going Phase 3 study, if successful, is likely to support the filing and approval of a New Drug Application ("NDA"). The statistical analysis plan and endpoints proposed by the Company were reviewed and accepted by the Division of Cardiovascular and Renal Products ("DcaRP") of the FDA. The exact indication to be sought by the Company, and to be reviewed by the FDA, would be driven by the study's results.